Gottlieb names names in promising support for generics

3 October 2017

A handful of branded examples were cited by Scott Gottlieb, Commissioner of the US Food and Drug Administration (FDA), as he outlined the need for generic versions of complex drugs where, in some cases, the original drug may retain exclusivity despite patents having expired.

Executive ears will be burning at Eli Lilly (NYSE: LLY), Novo Nordisk (NOV: N) and Teva Pharmaceutical Industries (NYSE: TEVA) after Dr Gottlieb wrote about making it easier to copy their drugs in a column published on Monday.

"Enabling more generic competition, where Congress intended, helps reduce prices, enable more access, and improve public health"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK